Future Market Insights (FMI)’ updated report on the asthma treatment market highlights several opportunities and growth prospects for the coming decade. As per the report, the asthma treatment market is set to surge from US$ 28.0 billion in 2024 and US$ 46.0 billion by 2034. The report reflects a robust CAGR of 5.1% between 2024 and 2034, inferring strong market growth.
| Attributes | Key Insights |
|---|---|
| Global Asthma Treatment Market Size (2024E) | US$ 28.0 billion |
| Market Value (2034F) | US$ 46.0 billion |
| Value-based CAGR (2024 to 2034) | 5.1% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The increasing incidence of asthma, growing knowledge about asthma medications, and advancements in asthma treatment choices are projected to spur market growth. The industry is further propelled by environmental factors such as air pollution, allergens, and lifestyle changes, which contribute to the surged prevalence of asthma worldwide.
Precision medicine is gaining traction in the asthma treatment industry as demand for individualized asthma medications increases. Mobile applications, smart inhalers, and wearable devices are improving tailored asthma therapy by allowing for real-time monitoring of symptoms, medication adherence, and lung function.
This accurate data gathering helps healthcare practitioners and professionals to understand each patient's asthma management better and offer appropriate treatment solutions.
Remote monitoring and telemedicine services are further estimated to enhance personalized treatment for patients in remote and underdeveloped areas. Pharmaceutical companies and research organizations are investing in innovating new drugs and therapies to meet the diverse needs of asthma patients globally.
Public health initiatives and awareness campaigns are further boosting market development. Urbanization, industrialization, genetic susceptibility, and family history of asthma are set to contribute to mounting asthma prevalence, creating an environment favorable for market growth.
From 2019 to 2023, bronchodilators such as theophylline and beta-agonists were primarily considered as asthma treatments, providing relief from symptoms. During 2019 and 2023, the market grew at a CAGR of 6.8%. Development in genetics and biomarker research has enabled personalized asthma treatment, optimizing its efficacy and minimizing side effects.
Digital health technologies, such as asthma management mobile apps, smart inhalers, and telemedicine services, further enabled better monitoring of asthma symptoms, medication adherence, and remote patient management.
Principal Consultant
Smart inhalers, smartphone applications, and telemedicine are improving asthma therapy by allowing for remote monitoring, medication adherence, and increased patient awareness and education. Preventive methods, such as environmental trigger reduction and lifestyle modifications aimed at reducing exacerbations and improving long-term treatment results, are set to fuel the market development.
Combination inhalers with bronchodilators and corticosteroids are gaining traction in asthma management due to their ease of use and improved patient outcomes. Healthcare policies, reimbursement structures, and value-based care initiatives are set to fuel asthma treatment adoption globally.
Leading companies and producers are focusing on developing novel therapeutic targets, drug delivery systems, and alternative treatments, propelling market development. The shift toward patient-centric care models, self-management education, and empowerment is gaining momentum in several emerging markets.
The section below highlights the projected growth rates of leading countries. Among these, South Korea is set to remain a highly lucrative market, exhibiting a CAGR of 7.2%. Japan and the United Kingdom are estimated to follow with CAGRs of 6.8% and 6.3%, respectively.
| Countries | Projected CAGR (2024 to 2034) |
|---|---|
| United States | 5.4% |
| United Kingdom | 6.3% |
| China | 5.9% |
| South Korea | 7.2% |
| Japan | 6.8% |
The asthma treatment industry can be observed in the subsequent tables, which focus on the leading economies, consisting of South Korea, Japan, the United Kingdom, China, and the United States. A comprehensive evaluation demonstrates that the United States has enormous potential for growth in the market.
| Countries | Market Values (2034) |
|---|---|
| United States | US$ 8.3 billion |
| United Kingdom | US$ 1.9 billion |
| China | US$ 7.3 billion |
| South Korea | US$ 3.0 billion |
| Japan | US$ 5.2 billion |
The United States is set to dominate the market by 2034, surging at a CAGR of 5.4%. Asthma, a common non-communicable disease in the United States, accounts for around 73% of outpatient clinic visits, creating a wide target population for effective asthma therapeutics.
Established healthcare infrastructure and increasing asthma prevalence in the United States are the key factors propelling market growth. The United States is further projected to grow significantly due to improved government reforms, a rising geriatric population, increasing healthcare expenditure, and growing consumer awareness about lung diseases.
By 2034, China is projected to grow substantially at a CAGR of 5.9%. Government initiatives, subsidies, and reimbursement policies to improve treatment quality, promote evidence-based practices, and reduce healthcare inconsistencies are influencing asthma therapy adoption in China.
Leading companies in China are focusing on research & development to innovate new therapeutic treatments, improve drug delivery systems, and understand asthma pathophysiology to reach wider customers.
The competitive asthma care market in China encourages innovation through collaborations and partnerships between industry stakeholders, academia, and patient advocacy groups.
Japan is projected to propel due to factors such as high asthma prevalence, increased consumer awareness, and innovations in treatment options. Developments in biologic medications and targeted therapies, which offer improved efficacy and fewer side effects, are estimated to fuel growth in the market.
The market in Japan is further anticipated to be influenced by increased FDA endorsements and key market strategies such as collaboration, mergers, and partnerships among local and international companies. The market's development is projected to be accelerated by key players intensifying their geographical presence in emerging nations. By 2034, Japan is projected to reach US$ 5.2 billion.
South Korea is home to several leading pharmaceutical companies specializing in asthma treatment, medication development, and manufacturing. These companies contribute to innovative asthma management therapies, propelling market growth in South Korea. South Korea is projected to reach a market valuation of US$ 3.0 billion in 2034.
South Korea's regulatory framework and favorable government reimbursement system encourage asthma treatment adoption, providing patients with a wide range of treatment options and fueling market reach.
South Korea is a leading center for asthma research and clinical trials, involving academic institutions, research centers, and healthcare organizations to develop new treatment methods.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The segmented market analysis is included in the subsequent section. Based on comprehensive studies, the inhaler segment is dominating the product category. Likewise, the oral segment is commanding the route of administration category.
| Segment | Value CAGR (2024 to 2034) |
|---|---|
| Inhalers (Product) | 4.8% |
| Oral (Route of Administration) | 4.6% |
The inhalers segment, with its reliability, versatility, portability, and cost-effectiveness, is projected to lead the product segment by 2034. The growing prevalence of asthma and COPD, along with the need for emergency treatment alternatives, is propelling the segment’s growth.
The development of progressive products, such as Trelegy Ellipta, a triple therapy inhaler approved in the United States, is also projected to fuel segment growth. Based on product, the inhaler segment is set to surge at a CAGR of 4.8% by 2034.
Based on the route of administration, the oral segment is set to rise at 4.6% CAGR by 2034. The segment is projected to witness a leading growth rate from 2024 to 2034 due to its convenience and efficacy.
Oral medications, taken by mouth and absorbed through the digestive system, are well-preferred and easy to use, making them popular among patients and healthcare providers. The convenience, effectiveness, and versatility of the oral route of administration make the segment a valuable tool for managing asthma, boosting the segment's growth.
Leading pharmaceutical companies are inclined toward research & development to surge their market reach while emerging biotech companies innovate targeted treatments to uphold their positions. Market growth relies on regulatory adherence, diagnostic research, strategic partnerships, and adapting to evolving consumer tastes.
For instance
The market is set to reach US$ 28.0 billion in 2024.
Demand for asthma treatment is slated to rise at a 5.1% CAGR by 2034.
The market is set to reach US$ 46.0 billion in 2034.
Teva Pharmaceutical Industries Ltd, GSK plc, Merck & Co.Inc, and AstraZeneca are the key players.
The inhaler segment is estimated to hold a significant market share in 2024.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Manufacturer
3.5.1.2. Mid-Level Participants (Traders)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
4.1. Historical Market Size Value (US$ million) & Volume (Units) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ million) & Volume (Units) Projections, 2024 to 2034
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Drug Class, 2019 to 2023
5.3. Current and Future Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Drug Class, 2024 to 2034
5.3.1. Anti-inflammatory
5.3.2. Bronchodilators
5.3.3. Combination Therapy
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Drug Class, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Product, 2019 to 2023
6.3. Current and Future Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Product, 2024 to 2034
6.3.1. Inhalers
6.3.1.1. Dry Powder
6.3.1.2. Metered Dose
6.3.1.3. Soft Mist
6.3.2. Nebulizers
6.4. Y-o-Y Growth Trend Analysis By Product, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By Product, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Route of Administration, 2019 to 2023
7.3. Current and Future Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Route of Administration, 2024 to 2034
7.3.1. Oral
7.3.2. Inhaled
7.3.3. Others
7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2019 to 2023
7.5. Absolute $ Opportunity Analysis By Route of Administration, 2024 to 2034
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Region, 2019 to 2023
8.3. Current Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Region, 2024 to 2034
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. South Asia and Pacific
8.3.6. East Asia
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
9.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023
9.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034
9.2.1. By Country
9.2.1.1. United States
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Product
9.2.4. By Route of Administration
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Product
9.3.4. By Route of Administration
9.4. Key Takeaways
10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
10.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023
10.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Product
10.2.4. By Route of Administration
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Product
10.3.4. By Route of Administration
10.4. Key Takeaways
11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
11.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Western Europe
11.2.2. By Drug Class
11.2.3. By Product
11.2.4. By Route of Administration
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Product
11.3.4. By Route of Administration
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Czech Republic
12.2.1.4. Romania
12.2.1.5. Rest of Eastern Europe
12.2.2. By Drug Class
12.2.3. By Product
12.2.4. By Route of Administration
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Product
12.3.4. By Route of Administration
12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Bangladesh
13.2.1.3. Australia
13.2.1.4. New Zealand
13.2.1.5. Rest of South Asia and Pacific
13.2.2. By Drug Class
13.2.3. By Product
13.2.4. By Route of Administration
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Product
13.3.4. By Route of Administration
13.4. Key Takeaways
14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Drug Class
14.2.3. By Product
14.2.4. By Route of Administration
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Product
14.3.4. By Route of Administration
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
15.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023
15.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of Middle East and Africa
15.2.2. By Drug Class
15.2.3. By Product
15.2.4. By Route of Administration
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Product
15.3.4. By Route of Administration
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. United States
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2024
16.1.2.1. By Drug Class
16.1.2.2. By Product
16.1.2.3. By Route of Administration
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2024
16.2.2.1. By Drug Class
16.2.2.2. By Product
16.2.2.3. By Route of Administration
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2024
16.3.2.1. By Drug Class
16.3.2.2. By Product
16.3.2.3. By Route of Administration
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2024
16.4.2.1. By Drug Class
16.4.2.2. By Product
16.4.2.3. By Route of Administration
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2024
16.5.2.1. By Drug Class
16.5.2.2. By Product
16.5.2.3. By Route of Administration
16.6. United Kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2024
16.6.2.1. By Drug Class
16.6.2.2. By Product
16.6.2.3. By Route of Administration
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2024
16.7.2.1. By Drug Class
16.7.2.2. By Product
16.7.2.3. By Route of Administration
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2024
16.8.2.1. By Drug Class
16.8.2.2. By Product
16.8.2.3. By Route of Administration
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2024
16.9.2.1. By Drug Class
16.9.2.2. By Product
16.9.2.3. By Route of Administration
16.10. Poland
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2024
16.10.2.1. By Drug Class
16.10.2.2. By Product
16.10.2.3. By Route of Administration
16.11. Russia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2024
16.11.2.1. By Drug Class
16.11.2.2. By Product
16.11.2.3. By Route of Administration
16.12. Czech Republic
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2024
16.12.2.1. By Drug Class
16.12.2.2. By Product
16.12.2.3. By Route of Administration
16.13. Romania
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2024
16.13.2.1. By Drug Class
16.13.2.2. By Product
16.13.2.3. By Route of Administration
16.14. India
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2024
16.14.2.1. By Drug Class
16.14.2.2. By Product
16.14.2.3. By Route of Administration
16.15. Bangladesh
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2024
16.15.2.1. By Drug Class
16.15.2.2. By Product
16.15.2.3. By Route of Administration
16.16. Australia
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2024
16.16.2.1. By Drug Class
16.16.2.2. By Product
16.16.2.3. By Route of Administration
16.17. New Zealand
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2024
16.17.2.1. By Drug Class
16.17.2.2. By Product
16.17.2.3. By Route of Administration
16.18. China
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2024
16.18.2.1. By Drug Class
16.18.2.2. By Product
16.18.2.3. By Route of Administration
16.19. Japan
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2024
16.19.2.1. By Drug Class
16.19.2.2. By Product
16.19.2.3. By Route of Administration
16.20. South Korea
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2024
16.20.2.1. By Drug Class
16.20.2.2. By Product
16.20.2.3. By Route of Administration
16.21. GCC Countries
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2024
16.21.2.1. By Drug Class
16.21.2.2. By Product
16.21.2.3. By Route of Administration
16.22. South Africa
16.22.1. Pricing Analysis
16.22.2. Market Share Analysis, 2024
16.22.2.1. By Drug Class
16.22.2.2. By Product
16.22.2.3. By Route of Administration
16.23. Israel
16.23.1. Pricing Analysis
16.23.2. Market Share Analysis, 2024
16.23.2.1. By Drug Class
16.23.2.2. By Product
16.23.2.3. By Route of Administration
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Drug Class
17.3.3. By Product
17.3.4. By Route of Administration
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Teva Pharmaceutical Industries Ltd.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.1.5.2. Product Strategy
18.1.1.5.3. Channel Strategy
18.1.2. GSK plc
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.2.5.2. Product Strategy
18.1.2.5.3. Channel Strategy
18.1.3. Merck & Co., Inc.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.3.5.2. Product Strategy
18.1.3.5.3. Channel Strategy
18.1.4. F. Hoffmann-La Roche Ltd
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.4.5.2. Product Strategy
18.1.4.5.3. Channel Strategy
18.1.5. AstraZeneca
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.5.5.2. Product Strategy
18.1.5.5.3. Channel Strategy
18.1.6. Boehringer Ingelheim International GmbH
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.6.5.2. Product Strategy
18.1.6.5.3. Channel Strategy
18.1.7. Sanofi.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.7.5.2. Product Strategy
18.1.7.5.3. Channel Strategy
18.1.8. Koninklijke Philips N.V.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.8.5.2. Product Strategy
18.1.8.5.3. Channel Strategy
18.1.9. BD
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.9.5.2. Product Strategy
18.1.9.5.3. Channel Strategy
18.1.10. Covis Pharma
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.10.5.2. Product Strategy
18.1.10.5.3. Channel Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Asthma Treatment Market
